Background:

Etofibrate is the ethandiol-1,2 diester of the nicotinic and clofibric acids. Etofibrate has been shown to be a potent hypolipidemic agent in animal and human.

Etofibrate is the ethandiol-1,2 diester of the nicotinic and clofibric acids. Etofibrate has been shown to be a potent hypolipidemic agent in animal and human. After 10 days of treatment with Etofibrate, the rats show a body weight similar to that found in the control animals but their liver weight is significantly enhanced whereas plasma cholesterol and triacylglycerol levels are decreased. Etofibrate treatment increases the bile flow of the animals, the effect being especially manifest during the first 2 hr after interruption of the enterohepatic circulation and the difference with the controls becomes statistically significant at 30 and 90 min. The cumulative amount of bile secreted plotted against time shows a highly significant linear correlation for both control and Etofibrate treated rats, the slope being significantly higher for the Etofibrate group than for controls[1].

参考文献:
[1]. Bocos C, et al. Effect of etofibrate on bile production in the normolipidemic rat. Gen Pharmacol. 1995 May;26(3):537-42.